Explore the latest local coverage updates for COSENTYX®
#1 covered IL-17 antagonist across all insurance types1*
The information provided is not a guarantee of coverage. Actual benefits are determined by each plan administrator in accordance with its policies and procedures.
Because formularies change and many health plans offer more than one formulary, please check with the health plan to confirm coverage for individual patients.
*COSENTYX for subcutaneous or intravenous use is present on formularies as either a first-, second-, third-, fourth-, or fifth-line biologic. Novartis does not guarantee payment or coverage for any product or service. Actual coverage and reimbursement decisions are made by individual payers following the receipt of claims. Coverage information is subject to change by the relevant payer. Based on the total number of covered lives across commercial, Medicare, and Medicaid health plans.
HS, hidradenitis suppurativa; IL, interleukin; IV, intravenous; PsA, psoriatic arthritis; PsO, plaque psoriasis; SC, subcutaneous.
Reference: 1. Data on file. IL-17 PsA Pharmacy Payer Coverage Data. Novartis Pharmaceuticals Corp; March 2025.
HS, hidradenitis suppurativa; IL, interleukin; IV, intravenous; PsA, psoriatic arthritis; PsO, plaque psoriasis; SC, subcutaneous.
Reference: 1. Data on file. IL-17 PsA Pharmacy Payer Coverage Data. Novartis Pharmaceuticals Corp; March 2025.